View full meeting coverage »

Eyetube Meeting Coverage:

OIS RETINA 2018

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Clearside Biomedical

  Channels: Retina | Posted 7/23/2018

Brion Raymond, Chief Commercial Officer, Clearside Biomedical, provides an update on the company’s lead product candidate, suprachoroidal CLS-TA, which is in clinical development for several indications including uveitis, retinal vein occlusion, and diabetic macular edema (DME).

Diabetic macular edema, DME • Retinal Vein Occlusion, RVO • suprachoroidal CLS-TA


7 / 11 Series: OIS RETINA 2018